Stat5 activation inhibits prolactin-induced AP-1 activity: Distinct prolactin-initiated signals in tumorigenesis dependent on cell context

Oncogene

Volumn 26, Issue 43, 2007, Pages 6341-6348

  Gutzman, J H ^a,b,c   Rugowski, D E ^b   Nikolai, S E ^b   Schuler, L A ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

AP 1; Breast cancer; Prolactin; Stat5

Indexed keywords

ESTRADIOL; GELATINASE A; PROLACTIN; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CELL; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION;

CELL LINE, TUMOR; HUMANS; NEOPLASMS; PHOSPHOTYROSINE; PROLACTIN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP-1;

EID: 34648831578     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210454     Document Type: Article

References (45)

1. Bjornstrom L, Sjoberg M. (2002). STAT as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16: 2202-2214.
2. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ. (1995). Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221: 706-718.
3. Brockman JL, Schroeder MD, Schuler LA. (2002). Prolactin activates the cyclin D1 promoter via the JAK2-STAT pathway. Mol Endocrinol 16: 774-784.
4. Bromberg J. (2002). Stat proteins and oncogenesis. J Clin Invest 109: 1139-1142.
5. Buettner R, Mora LB, Jove R. (2002). Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 8: 945-954.
6. +/taurocholate cotransporting polypeptide in liver cells through estrogen receptor-α and STAT5a. Endocrinology 145: 1739-1749.
7. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. (2003). Role of prolactin in mammary carcinoma. Endocr Rev 24: 1-27.
8. Cotarla I, Ren SX, Zhang Y, Gehan E, Singh B, Furth PA. (2004). Stat5a is tyrosine phosphorylated and nuclear localized in a high proportion of human breast cancers. Int J Cancer 108: 665-671.
9. DaSilva L, Rui H, Erwin RA, Howard OM, Kirken RA, Malabarba MG et al. (1996). Prolactin recruits STAT1, STAT3 and STAT5 independent of conserved receptor tyrosines TYR402, TYR479, TYR515 and TYR580. Mol Cell Endocrinol 117: 131-140.
10. Eferl R, Wagner EF. (2003). AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868.
11. Faulds MH, Pettersson K, Gustafsson JA, Haldosen LA. (2001). Cross-talk between ERs and Stat5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 15: 1929-1940.
12. Gee JM, Barroso AF, Ellis IO, Robertson JF, Nicholson RI. (2000). Biological and clinical associations of c-jun activation in human breast cancer. Int J Cancer 89: 177-186.
13. Goffin V, Bernichtein S, Touraine P, Kelly PA. (2005). Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 26: 400-422.
14. Gutzman JH, Nikolai SE, Rugowski DE, Watters JJ, Schuler LA. (2005). Prolactin and estrogen enhance the activity of AP-1 in breast cancer cells: role of ERK1/2-mediated signals to c-fos. Mol Endocrinol 19: 1765-1778.
15. Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA. (2004). Multiple kinase cascades mediate prolactin signals to AP-1 in breast cancer cells. Mol Endocrinol 18: 3064-3075.
16. Hennighausen L, Robinson GW. (2005). Information networks in the mammary gland. Nat Rev Mol Cell Biol 6: 715-725.
17. Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen TM et al. (1997). Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA 94: 1074-1079.
18. Humphreys RC, Hennighausen L. (1999). STAT5a influences mammary epithelial cell survival and tumorigenesis. Cell Growth Differ 10: 685-694.
19. Iavnilovitch E, Groner B, Barash I. (2002). Overexpression and forced activation of Stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Cell Growth Differ 1: 32-47.
20. Ilaria Jr RL, Hawley RG, Van Etten RA. (1999). Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood 93: 4154-4166.
21. Johnston SR, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M et al. (1999). Increased AP-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251-256.
22. Keely PJ. (2001). Ras and Rho protein induction of motility and invasion in T47D breast adenocarcinoma cells. Methods Enzymol 333: 256-266.
23. Levy DE, Darnell Jr JE. (2002). Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3: 651-662.
24. Luo GY, Yu-Lee LY. (2000). Stat5b inhibits NFkappaB-mediated signaling. Mol Endocrinol 14: 114-123.
25. Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Loning T. (2000). Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of AP-1 family members. Int J Cancer 87: 468-472.
26. Milde-Langosch K, Roder H, Andritzky B, Aslan B, Hemminger G, Brinkmann A et al. (2004). The role of the AP-1 transcription factors c-Fos, FosB, Fra-1 and Fra-2 in the invasion process of mammary carcinomas. Breast Cancer Res Treat 86: 139-152.
27. Nakamura T, Ouchida R, Kodama T, Kawashima T, Makino Y, Yoshikawa N et al. (2002). Cytokine receptor common beta subunit-mediated STAT5 activation confers NF-kappa B activation in murine proB cell line Ba/F3 cells. J Biol Chem 277: 6254-6265.
28. Nevalainen MT, Xie J, Torhorst J, Bubendorf L, Haas P, Kononen J et al. (2004). Stat-5 activation and breast cancer prognosis. J Clin Oncol 22: 2053-2060.
29. Nouhi Z, Chughtai N, Hartley S, Cocolakis E, Lebrun JJ, Ali S. (2006). Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 66: 1824-1832.
30. Ormandy CJ, Horseman ND, Naylor MJ, Harris J, Robertson F, Binart N et al. (2001). Mammary gland development. Prolactin In: Horseman ND (ed). Kluwer Academic Publishers: Boston, pp. 219-232.
31. Ren S, Cai HR, Li M, Furth PA. (2002). Loss of Stat5a delays mammary cancer progression in a mouse model. Oncogene 21: 4335-4339.
32. Schroeder MD, Symowicz J, Schuler LA. (2002). Prolactin modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol 16: 45-57.
33. Shaulian E, Karin M. (2002). AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-E136.
34. Shemanko CS, Groner B. (2001). Transcription factors, cofactors and target genes mediating prolactin signals. Prolactin In: Horseman ND (ed). Kluwer Academic Publishers: Boston, pp. 381-404.
35. Shuai K. (2000). Modulation of STAT signaling by STAT-interacting proteins. Oncogene 19: 2638-2644.
36. Sultan AS, Xie J, LeBaron MJ, Ealley EL, Nevalainen MT, Rui H. (2005). Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 24: 746-760.
37. Tworoger SS, Hankinson SE. (2006). Prolactin and breast cancer risk. Cancer Lett 243: 160-169.
38. Van't Veer LJ, Dai HY, Van de Vijver MJ, He YDD, Hart AAM, Mao M et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
39. Vincenti MP. (2001). The matrix metalloproteinase and tissue inhibitor of metalloproteinase genes. Transcriptional and posttranscriptional regulation, signal transduction and cell-type-specific expression. Methods Mol Biol 151: 121-148.
40. Vonderhaar BK. (2000). Prolactin in Human Breast Cancer Development. Endocrine Oncology In: Ethier SP (ed). Humana Press: Totowa, NJ, pp. 101-120.
41. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. (2005). Gene expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
42. Watson CJ. (2001). Stat transcription factors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 6: 115-127.
43. Weaver AM, Silva CM. (2006). Modulation of Stat5b activity in breast cancer cells by mutation of tyrosines within the transactivation domain. Mol Endocrinol 20: 2392-2405.
44. Yang E, Lerner L, Besser D, Darnell Jr JE. (2003). Independent and cooperative activation of chromosomal c-fos promoter by STAT3. J Biol Chem 278: 15794-15799.
45. Zhang X, Wrzeszczynska MH, Horvath CM, Darnell Jr JE. (1999). Interacting regions in Stat3 and c-Jun that participate in cooperative transcriptional activation. Mol Cell Biol 19: 7138-7146.